Truist analyst Robyn Karnauskas raised the firm’s price target on Eli Lilly to $600 from $525 and keeps a Buy rating on the shares. The stock rally yesterday was driven by SELECT study read-through to Mounjaro CV outcomes data and potential to improve reimbursement and the continued uptake of Mounjaro in T2D, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY: